INNOVATIVE PARTNERSHIPS IN TYPE 1 DIABETES RESEARCH

Release Date:  October 2, 2001

RFA:  RFA-DK-02-023

National Institute of Diabetes and Digestive and Kidney Diseases
 (http://www.niddk.nih.gov)
National Institute of Allergy and Infectious Diseases
 (http://www.niaid.nih.gov/)
National Eye Institute
 (http://www.nei.nih.gov/)
National Institute of Nursing Research
 (http://www.ninr.nih.gov/)
National Heart, Lung, and Blood Institute
 (http://www.nhlbi.nih.gov/)

Letter of Intent Receipt Date:  February 14, 2002
Application Receipt Date:       March 14, 2002

THIS RFA USES "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS.  MODULAR 
INSTRUCTIONS MUST BE USED FOR RESEARCH GRANT APPLICATIONS REQUESTING LESS 
THAN $250,000 PER YEAR IN ALL YEARS. MODULAR BUDGET INSTRUCTIONS ARE PROVIDED 
IN SECTION C OF THE PHS 398 (REVISION 5/2001) AVAILABLE AT 
http://grants.nih.gov/grants/funding/phs398/phs398.html.

PURPOSE

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 
National Institute of Allergy and Infectious Diseases (NIAID), National Eye 
Institute (NEI), National Institute of Nursing Research (NINR), and National 
Heart, Lung, and Blood Institute (NHLBI) invite applications to support 
collaborations between investigators who focus their research efforts on type 
1 diabetes or its complications and researchers from other research areas 
with expertise relevant to type 1 diabetes research. The purpose of this 
Request for Applications (RFA) is to attract new research talent to type 1 
diabetes research, strengthen the ongoing efforts of type 1 diabetes 
researchers by providing access to specialized expertise or technologies 
relevant to their research, and facilitate the formation of interdisciplinary 
research partnerships to investigate significant biological and medical 
problems associated with type 1 diabetes.  Applications should propose 
collaborative research partnerships between independent principal 
investigators-- one currently pursuing research relevant to type 1 diabetes 
and one (or more) with expertise relevant to some aspect of type 1 diabetes, 
which is not currently being applied by the investigator to research on this 
disease.  This RFA encourages type 1 diabetes researchers to act as “talent 
scouts” and to actively identify and recruit leading scientists with relevant 
scientific expertise to the field of type 1 diabetes research.

HEALTHY PEOPLE 2010

The Public Health Service (PHS) is committed to achieving the health 
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas.  This RFA, Innovative 
Partnerships in Type 1 Diabetes Research, is related to one or more of the 
priority areas.  Potential applicants may obtain a copy of "Healthy People 
2010" at http://www.health.gov/healthypeople/.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign for-profit and 
nonprofit organizations, public and private, such as universities, colleges, 
hospitals, laboratories, units of State and local governments, and eligible 
agencies of the Federal government.  Racial/ethnic minority individuals, 
women, and persons with disabilities are encouraged to apply as principal 
investigators.

MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) exploratory pilot 
and feasibility project grant (R21) award mechanism.  Responders to this 
initiative may be new or experienced investigators with independent research 
support who are able to develop new and innovative approaches to study type 1 
diabetes.  Either of the research partners may serve as the principal 
investigator, and the research partners do not have to be from the same 
research institution.  

Generally, pilot and feasibility proposals are expected to have little 
preliminary data and are reviewed based on the development of hypotheses and 
supporting literature.  While no preliminary data from the collaboration is 
required, applicants should include some preliminary data relevant to the 
proposed project from the partner currently working in the area of type 1 
diabetes.  Information documenting the ability of the collaborator regarding 
the technology or expertise s/he will be providing to the partnership should 
also be provided. Responsibility for the planning, direction, and execution 
of the proposed project will be solely that of the applicant.  The maximum 
budget request for R21 applications submitted in response to this RFA may not 
exceed $250,000 in direct costs per year, and may not exceed two years for 
the total project period.

Applicants from institutions that have a Diabetes Endocrinology Research 
Center (DERC), a Diabetes Research and Training Center (DRTC), or a General 
Clinical Research Center (GCRC) funded by the NIH National Center for 
Research Resources may wish to identify the Center(s) as a resource for 
conducting the proposed research.   In such a case, a letter of agreement 
from either the principal investigator or the GCRC program director should be 
included with the application.  

Specific application instructions have been modified to reflect "MODULAR 
GRANT" and "JUST-IN-TIME" streamlining efforts that have been adopted by the 
NIH. Complete and detailed instructions and information on Modular Grant 
applications have been incorporated into the PHS 398 (rev. 5/2001).  
Additional information on Modular Grants can be found at 
http://grants.nih.gov/grants/funding/modular/modular.htm 

This RFA is a one-time solicitation.  Future unsolicited competing 
continuation applications will compete with all investigator-initiated 
applications and will be reviewed according to the customary peer review 
procedures.  The anticipated award date is September 30, 2002.

FUNDS AVAILABLE

The sponsoring institutes intend to commit approximately $4 million in FY 
2002 to fund 12 to 15 new grants in response to this RFA. An applicant may 
request a project period of up to 2 years and a budget for direct costs of up 
to $250,000 per year, excluding indirect costs on consortium arrangements.  
Because the nature and scope of the research proposed may vary, it is 
anticipated that the size of each award will also vary. Although the 
financial plans of the sponsoring institutes provide support for this 
program, awards pursuant to this RFA are contingent upon the availability of 
funds and the receipt of a sufficient number of applications of outstanding 
scientific and technical merit.

RESEARCH OBJECTIVES

Background

Type 1 diabetes is an autoimmune disease characterized by the destruction of 
the insulin-secreting beta cells of the pancreas by cytotoxic T cells.  The 
incidence of type 1 diabetes appears to be increasing worldwide.  Although 
the disease may occur at any age, the onset of type 1 diabetes peaks prior to 
twenty years of age.  In some populations, about one percent of all newborns 
will develop type 1 diabetes during their lifetime.  Those affected with type 
1 diabetes suffer from devastating complications including accelerated onset 
of cardiovascular and peripheral vascular diseases, neuropathy, nephropathy, 
retinopathy and premature mortality.

Objectives and Scope

The objectives of this RFA are to attract new research talent to type 1 
diabetes research, strengthen the ongoing efforts of type 1 diabetes 
researchers by providing access to specialized expertise or technologies 
relevant to their research, and facilitate the formation of interdisciplinary 
research partnerships to investigate significant biological and medical 
problems associated with type 1 diabetes.  Established type 1 diabetes 
researchers are encouraged to act as “talent scouts” and to actively identify 
and recruit leading scientists with relevant scientific expertise to the 
field of type 1 diabetes research.  
 
Generally, pilot and feasibility applications are expected to have little 
preliminary data and are reviewed based on the development of hypotheses and 
supporting literature.  While no preliminary data from the collaboration 
between the two investigators mentioned above is required, applicants should 
include some preliminary data relevant to the proposed project from the 
partner currently working in the area of type 1 diabetes.  Some information 
documenting the ability of the collaborator regarding the technology or 
expertise s/he will be providing to the partnership should also be provided.

Applications should propose collaborative research partnerships between 
independent principal investigators-- one currently pursuing research 
relevant to type 1 diabetes and one (or more) with expertise relevant to some 
aspect of type 1 diabetes, which is not currently being applied by the 
investigator to research on this disease.  Although it is not a requirement 
that the research partner(s) being recruited to diabetes research should 
never have worked on a project relevant to diabetes or its complications, 
diabetes-related research should not have been a significant focus of his/her 
research effort.  Review criteria (see below) will include consideration of 
whether one partner is new to diabetes research and is likely to make 
substantial contributions to the diabetes research effort.  The application 
will be judged in the context of the objectives of the RFA (see above); a 
major objective is attracting new talent to diabetes research.  

Each of the research partners should be a successful independent investigator 
with a track record of successful research accomplishments.   

The collaborating investigators need not be at the same institution.  If at 
separate institutions, the application should document how the collaboration 
will be achieved.  One potential mechanism for collaboration between two 
independent laboratories might be a shared postdoctoral fellow or other 
research staff position.  Funds for travel between the collaborating 
laboratories can be included in the budget proposal.  

Either of the research partners may serve as principal investigator for the 
joint application.  The level of effort proposed by the collaborating 
independent investigators should be appropriate for the scope of the project.

R21 applications submitted in response to this RFA may address any topic 
relevant to type 1 diabetes and its complications ranging from fundamental 
research on etiology and pathogenesis to applied research focused on the 
development of methods for prevention, improved treatment, or cure.  R21 
applications may involve collaborations between diabetes researchers and 
investigators in diverse fields including, but not limited to, cardiovascular 
disease, nephrology, ophthalmology, neuroscience, molecular virology, 
immunology, infectious disease, genetics, epidemiology, behavioral and/or 
psychosocial research, biophysics, materials science, bioengineering, 
bioimaging, developmental biology, cell biology, cell signaling, structural 
biology, genomics, proteomics, or bioinformatics.

Examples of types of research projects that are responsive to this RFA 
include but are not limited to:

o Development and/or testing of strategies to prevent or reverse type 1 
diabetes and its macro and microvascular complications

o Research to discover the biochemical mechanisms by which diabetes genes 
function to create susceptibility to diabetes and its complications

o Identification of viral or environmental triggers of type 1 diabetes and 
mechanisms by which such triggers initiate an autoimmune response
  
o Development and/or testing of glucose sensors and/or insulin delivery 
devices that offer advantages over current devices 

o Research to identify islet stem cells, understand their differentiation, 
growth and development, and develop improved methods for isolation, 
maintenance, growth and propagation, or differentiation of beta cells/islets  

o Research on signaling pathways involved in the regulation of normal 
pancreatic beta cell function

o Research on strategies to develop new or improved sources of beta 
cells/islets or to enhance the regeneration or viability of beta cells/islets

o Development and/or testing of improved methods of immunoalteration of beta 
cells/islets or of the immune response in an attempt to prevent autoimmune 
and host-versus-graft destruction of beta cells/islets

o Development of immunobarrier technology to protect transplanted islets or 
engineered insulin-producing cells from autoimmune destruction or rejection

o Definition of the genetic, molecular or cellular processes and the sequence 
of events in the pathogenesis of hyperglycemia-induced injury so that 
potential sites for intervention can be identified

o Development or testing of innovative pharmacological agents and 
interventions to prevent or halt the progression of type 1 diabetes or its 
long-term complications

o Development of  animal models of type 1 diabetes and its complications 
which closely parallel the human disease useful for exploring the 
pathogenesis and therapy of  type 1 diabetes or its complications 

o Development of strategies and tools to improve diabetes management and 
outcomes

o Development of tests that will facilitate clinical trials such as measures 
of risk for diabetes and/or complications or measures of response to therapy

INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS

It is the policy of the NIH that women and members of minority groups and 
their sub-populations must be included in all NIH-supported biomedical and 
behavioral research projects involving human subjects, unless a clear and 
compelling rationale and justification are provided indicating that inclusion 
is inappropriate with respect to the health of the subjects or the purpose of 
the research.  This policy results from the NIH Revitalization Act of 1993 
(Section 492B of Public Law 103-43). 

All investigators proposing research involving human subjects should read the 
UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in 
Clinical Research," published in the NIH Guide for Grants and Contracts on 
August 2, 2000 
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html); 
a complete copy of the updated Guidelines are available at 
http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm:  The 
revisions relate to NIH defined Phase III clinical trials and require: a) all 
applications or proposals and/or protocols to provide a description of plans 
to conduct analyses, as appropriate, to address differences by sex/gender 
and/or racial/ethnic groups, including subgroups if applicable; and b) all 
investigators to report accrual, and to conduct and report analyses, as 
appropriate, by sex/gender and/or racial/ethnic group differences.

INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS.

It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted or supported by 
the NIH, unless there are scientific and ethical reasons not to include them.  
This policy applies to all initial (Type 1) applications submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
“NIH Policy and Guidelines on the Inclusion of Children as Participants in 
Research Involving Human Subjects” that was published in the NIH Guide for 
Grants and Contracts, March 6, 1998, and is available at the following URL 
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html.

Investigators may also obtain copies of these policies from the program staff 
listed under INQUIRIES.  Program staff may also provide additional relevant 
information concerning the policy.

REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS
NIH policy requires education on the protection of human subject participants 
for all investigators submitting NIH proposals for research involving human 
subjects.  This policy announcement is found in the NIH Guide for Grants and 
Contracts Announcement dated June 5, 2000, at the following website: 
http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within 
specified page limitations. Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no obligation 
to view the Internet sites. Reviewers are cautioned that their anonymity may 
be compromised when they directly access an Internet site.

PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT
The Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) 
cited publicly and officially by a Federal agency in support of an action 
that has the force and effect of law (i.e., a regulation) may be accessed 
through FOIA.  It is important for applicants to understand the basic scope 
of this amendment.  NIH has provided guidance at: 
http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm
Applicants may wish to place data collected under this RFA in a public 
archive, which can provide protections for the data and manage the 
distribution for an indefinite period of time.  If so, the application should 
include a description of the archiving plan in the study design and include 
information about this in the budget justification section of the 
application. In addition, applicants should think about how to structure 
informed consent statements and other human subjects procedures given the 
potential for wider use of data collected under this award.

LETTER OF INTENT 

Prospective applicants are asked to submit, by February 14, 2002, a letter of 
intent that includes a descriptive title of the proposed research; the name, 
address, and telephone number of the Principal Investigator; the identities 
of other key personnel and participating institutions; and the number and 
title of the RFA in response to which the application may be submitted.

Although a letter of intent is not required, is not binding, and does not 
enter into the review of a subsequent application, the information that it 
contains allows NIDDK staff to estimate the potential review workload and 
plan the review.

The letter of intent is to be sent to:

Chief, Review Branch 
Division of Extramural Activities, NIDDK
6707 Democracy Boulevard, Rm. 752 MSC 5452
Bethesda, MD  20892-5452
(for express/courier service: Bethesda, MD  20817)
Telephone:  (301) 594-8885
FAX:  (301) 480-3505

APPLICATION PROCEDURES

The PHS 398 research grant application instructions and forms (rev. 5/2001) 
at http://grants.nih.gov/grants/funding/phs398/phs398.html must be used in 
applying for these grants. This version of the PHS 398 is available in an 
interactive, searchable PDF format. Beginning January 10, 2002, however, the 
NIH will return applications that are not submitted on the 5/2001 version.  
For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: 
GrantsInfo@nih.gov.

All application instructions outlined in the PHS 398 application kit are to 
be followed, with the following requirements for R21 applications:  

1.  R21 applications will use the “MODULAR GRANT” and “JUST-IN-TIME” 
concepts, with direct costs requested in $25,000 modules, up to the total 
direct costs limit of $250,000 per year. 

2. Although preliminary data are not required for an R21 application, they 
may be included.

SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS    

The modular grant concept establishes specific modules in which direct costs 
may be requested as well as a maximum level for requested budgets. Only 
limited budgetary information is required under this approach.  The 
just-in-time concept allows applicants to submit certain information only 
when there is a possibility for an award. It is anticipated that these 
changes will reduce the administrative burden for the applicants, reviewers 
and NIH staff.  The research grant application form PHS 398 (rev. 5/2001) at 
http://grants.nih.gov/grants/funding/phs398/phs398.html is to be used in 
applying for these grants, with modular budget instructions provided in 
Section C of the application instructions. 

The RFA label available in the PHS 398 (rev. 5/2001) application form must be 
affixed to the bottom of the face page of the application.  Type the RFA 
number on the label.  Failure to use this label could result in delayed 
processing of the application such that it may not reach the review committee 
in time for review.  In addition, the RFA title and number must be typed on 
line 2 of the face page of the application form and the YES box must be 
marked. The RFA label is also available at: 
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf.

Submit a signed, typewritten original of the application, including the 
Checklist, and three signed photocopies, in one package to:

CENTER FOR SCIENTIFIC REVIEW
National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD  20892-7710
Bethesda, MD  20817 (for express/courier service)

At time of submission, two additional copies of the application must be sent to:

Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
6707 Democracy Boulevard, Room 752 MSC 5452
Bethesda, MD  20892-5452
(for express/courier service: Bethesda, MD  20817)

Applications must be received by the application receipt date listed in the 
heading of the RFA.  If an application is received after that date, it will 
be returned to the applicant without review. Supplemental documents 
containing significant revision or additions will not be accepted, unless 
applicants are notified by the Scientific Review Administrator.  

The Center for Scientific Review (CSR) will not accept any application in 
response to this RFA that is essentially the same as one currently pending 
initial review, unless the applicant withdraws the pending application.  The 
CSR will not accept any application that is essentially the same as one 
already reviewed.  This does not preclude the submission of substantial 
revisions of applications previously reviewed, but such applications must 
include an Introduction addressing the previous critique.

REVIEW CONSIDERATIONS

Upon receipt, applications will be reviewed for completeness by the CSR and 
responsiveness by the NIDDK.  Incomplete and/or non-responsive applications 
will be returned to the applicant without further consideration. 
 
Applications that are complete and responsive to the RFA will be evaluated 
for scientific and technical merit by an appropriate peer review group 
convened by the NIDDK in accordance with the review criteria stated below.  
As part of the initial merit review, all applications will receive a written 
critique and undergo a process in which only those applications deemed to 
have the highest scientific merit, generally the top half of the applications 
under review, will be discussed, assigned a priority score, and receive a 
second level review by the appropriate NIH Advisory Council.

Review Criteria

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments, reviewers will be asked to discuss the following 
aspects of the application in order to judge the likelihood that the proposed 
research will have a substantial impact on the pursuit of these goals.  Each 
of these criteria will be addressed and considered in assigning the overall 
score, weighting them as appropriate for each application.  Note that the 
application does not need to be strong in all categories to be judged likely 
to have major scientific impact and thus deserve a high priority score.  For 
example, an investigator may propose to carry out important work that by its 
nature is not innovative but is essential to move a field forward.

(1) Significance:  Does this study address an important problem in type 1 
diabetes research?  If the aims of the application are achieved, how will 
scientific knowledge be advanced?  What will be the effect of these studies 
on the concepts or methods that drive this field?

(2) Approach:  Are the conceptual framework, design, methods, and analyses 
adequately developed, well-integrated, and appropriate to the aims of the 
project?  Does the applicant acknowledge potential problem areas and consider 
alternative tactics?

(3) Innovation:  Does the project employ novel concepts, approaches or 
methods? Are the aims original and innovative?  Does the project challenge 
existing paradigms or develop new methodologies or technologies? 

(4) Investigators:  Are the investigators appropriately trained and well 
suited to carry out this work?  Is the work proposed appropriate to the 
experience level of the principal investigator and other researchers? Is the 
research partnership innovative?  Does the partnership include an independent 
investigator new to type 1 diabetes research with appropriate expertise to 
contribute significantly to diabetes research?  Is the research partnership 
interdisciplinary and does it merge scientific expertise based upon strong 
experimental rationale and sound project goals?  

(5) Environment:  Does the scientific environment in which the work will be 
done contribute to the probability of success?  Do the proposed experiments 
take advantage of unique features of the scientific environment or employ 
useful collaborative arrangements?  Is there evidence of institutional 
support?

In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

o  Adequacy of plans to include both genders, minorities and their subgroups, 
and children as appropriate for the scientific goals of the research.  Plans 
for the recruitment and retention of subjects will also be evaluated.  

o  The reasonableness of the proposed budget and duration to the proposed 
research.

o  The adequacy of the proposed protection of humans or the environment, to 
the extent that they may be adversely affected by the project proposed in the 
application.

o  Availability of special opportunities for furthering research programs 
through the use of unusual talent resources, populations, or environmental 
conditions in other countries which are not readily available in the United 
States or which provide augmentation of existing U.S. resources.

Schedule

Letter of Intent Receipt Date:    February 14, 2002
Application Receipt Date:         March 14, 2002
Peer Review Date:                 June/July, 2002
Council Review:                   September, 2002
Earliest Anticipated Start Date:  September 30, 2002

AWARD CRITERIA

Award criteria that will be used to make award decisions include:

o Scientific merit as determined by peer review;
o Availability of funds;
o Programmatic priorities.

INQUIRIES

Inquiries concerning this RFA are encouraged.  The opportunity to clarify any 
issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

James F. Hyde, Ph.D. 
Division of Diabetes, Endocrinology and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health 
6707 Democracy Boulevard, Rm. 603, MSC 5460
Bethesda, MD  20892-5460
Telephone:  (301) 594-7692
FAX:  (301) 435-6047
E-mail:  jh486z@nih.gov

Elaine Collier, M.D.  
Division of Allergy, Immunology, and Transplantation 
NIAID 
6700-B Rockledge Drive, Room 5135, MSC 7640 
Bethesda, MD  20892-7640 
Telephone:  (301) 496-7104 
FAX:  (301) 402-2571 
E-mail:  ec5x@nih.gov

Peter A. Dudley, Ph.D.
Division of Extramural Research
National Eye Institute
Executive Plaza South, Suite 350
Bethesda, MD  20892-7164
Telephone:  (301) 496-0484
FAX:  (301) 402-0528
Email:  pad@nei.nih.gov

Nell Armstrong, Ph.D., R.N.
Program Director
National Institute of Nursing Research
National Institutes of Health
Building 45, Room 3AN-12
Bethesda MD  20892-6300
Telephone:  (301) 594-5973
FAX:  (301) 480-8260
E-mail:  na21f@nih.gov

Momtaz Wassef, Ph.D.
Leader, Atherosclerosis Research Group
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 10186
Bethesda, MD  20892-7956
Telephone:  (301) 435-0550 
FAX:  (301) 480-2848
E-mail:  mw47d@nih.gov

Direct inquiries regarding fiscal matters to:

Donald Ellis
Grants Management Branch
Division of Extramural Activities 
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 709B MSC 5456
Bethesda, MD  20892-5456
Telephone:  (301) 594-8849 
FAX:  (301) 594-9523
E-mail:  de30z@nih.gov

Pamela G. Fleming 
Grants Management Officer
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases 
6700-B Rockledge Drive, Room 2119, MSC 7614 
Bethesda, MD  20892-7614 (Regular Mail) 
Bethesda, MD  20817 (Express Mail) 
Phone:  (301) 402-6580 
FAX:  (301) 493-0597 
E-mail:  pf49e@nih.gov

Margie Baritz
Grants Management Specialist
National Eye Institute
6120 Executive Blvd
Suite 350, MSC 7164
Bethesda, MD  20892-7164
Telephone:  (301) 496-5884
FAX:  (301) 496-9977
E-mail:  mb41k@nih.gov

Robert L. Tarwater
Grants Management Specialist
Office of Grants and Contracts Management
National Institute of Nursing Research
National Institutes of Health
Building 45, Room 3AN.12
Bethesda, Maryland  20892-6300
Telephone:  (301) 594-2807
FAX:  (301) 480-8260
E-mail:  rt28o@nih.gov

Ms. Jane Davis
Grants Operations Branch
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 7156
Bethesda, MD  20892-7926
Telephone:  (301)435-0166
FAX:  (301)480-3310
E-mail:  jd53j@nih.gov

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance No. 
93.847 (NIDDK), 93.855, Immunology, Allergy and Transplantation Research 
(NIAID), 93.867 (NEI), 93.361 (NINR), and 93.837 (NHLBI).  Awards are under 
authorization of the Public Health Service Act, Title IV, Part A (Public Law 
78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered 
under NIH grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts 
74 and 92.  This program is not subject to the intergovernmental review 
requirements of Executive Order 12372 or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a 
smoke-free workplace and promote the non-use of all tobacco products.  In 
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking 
in certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care or early 
childhood development services are provided to children.   This is consistent 
with the PHS mission to protect and advance the physical and mental health of 
the American people.

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files.